These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29271114)

  • 1. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
    Fourati S; Guedj J; Chevaliez S; Nguyen THT; Roudot-Thoraval F; Ruiz I; Soulier A; Scoazec G; Varaut A; Poiteau L; Francois M; Mallat A; Hézode C; Pawlotsky JM
    Aliment Pharmacol Ther; 2018 Mar; 47(5):665-673. PubMed ID: 29271114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Jul; 89(7):1248-1254. PubMed ID: 28079269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    J Gastroenterol; 2017 Jul; 52(7):845-854. PubMed ID: 27913920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
    J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
    Hu C; Yuan G; Liu J; Huang H; Ren Y; Li Y; Chen X; Li W; Wu T; Deng H; Peng Y; Zhang YY; Zhou Y
    Can J Gastroenterol Hepatol; 2018; 2018():3908767. PubMed ID: 30538973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
    Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Fujisaki K; Hashiguchi M; Inada Y; Uto H; Hiramine Y; Kure T; Hori T; Taniyama O; Kasai A; Tamai T; Moriuchi A; Ido A
    PLoS One; 2018; 13(6):e0198642. PubMed ID: 29856885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
    Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
    N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.
    Wyles D; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Martin R; Afdhal NH; Kowdley KV; Lawitz E; Brainard DM; Miller MD; Mo H; Gane EJ
    J Hepatol; 2017 Apr; 66(4):703-710. PubMed ID: 27923693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
    Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
    Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    Suda G; Ogawa K; Yamamoto Y; Katagiri M; Furuya K; Kumagai K; Konno J; Kimura M; Kawagishi N; Ohara M; Umemura M; Ito J; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Tsubota A; Shimada N; Iio E; Tanaka Y; Sakamoto N;
    J Gastroenterol; 2017 Oct; 52(10):1122-1129. PubMed ID: 28315983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
    Kozuka R; Hai H; Motoyama H; Hagihara A; Fujii H; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
    J Viral Hepat; 2018 May; 25(5):535-542. PubMed ID: 29274188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
    Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
    J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
    Lau G; Benhamou Y; Chen G; Li J; Shao Q; Ji D; Li F; Li B; Liu J; Hou J; Sun J; Wang C; Chen J; Wu V; Wong A; Wong CL; Tsang ST; Wang Y; Bassit L; Tao S; Jiang Y; Hsiao HM; Ke R; Perelson AS; Schinazi RF
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):97-104. PubMed ID: 27917405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
    Latt NL; Yanny BT; Gharibian D; Gevorkyan R; Sahota AK
    World J Gastroenterol; 2017 Jul; 23(26):4759-4766. PubMed ID: 28765697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.
    Singh A; Kumari S; Kumar P; De A; Singh V
    J Viral Hepat; 2018 Dec; 25(12):1501-1506. PubMed ID: 30113115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.